证券之星消息，2025年11月19日迈得医疗（688310）发布公告称公司于2025年11月19日召开业绩说明会。 答：尊敬的投资者朋友，您好！公司资金持续聚焦主业发展，丰富产品矩阵，同时将根据发展规划，继续对隐形眼镜 业务开展相关材料研发、产品取证、自主品牌运营、新产品开发、产线优化降本等工作，致力打通隐形眼镜上下游产 业链。感谢您的支持与关注！ 问：请林总，公司隐形眼镜的产能是否跟得上？在线上平台经常出现缺货情况，公司日抛产品什么时候可以上？ 具体内容如下： 问：答环节： 答：问环节 问：请今年三季度公司核心产品的市场需求和价格走势整体表现如何，哪些业务板块为业绩增长贡献了主要力量呢？ 答：尊敬的投资者朋友，您好！公司产品为非标定制化智能设备，根据产品的规格型号及客户定制需求等方面的要 求，遵循公平、自愿原则，经双方协商一致确定交易定价。目前公司核心产品为安全输注类、血液净化类智能装备， 并推广药械组合类智能装备，以上产品均为公司业绩增长贡献力量。感谢您的支持与关注！ 问：请公司 2025 年三季度营收情况如何？是否完成预期了呢? 答：尊敬的投资者朋友，您好！公司截至 2025 年三季度累计实现营业收入 ...

Core Viewpoint - Midea Medical experienced a decline of 5.33% in stock price, reaching 19.91 CNY per share, with a total market capitalization of 3.309 billion CNY as of October 28 [1] Company Overview - Midea Medical Industrial Equipment Co., Ltd. is located in Yuhuan City, Zhejiang Province, established on March 10, 2003, and listed on December 3, 2019 [1] - The company's main business involves the research, production, sales, and service of medical consumable intelligent equipment [1] - Revenue composition includes: 48.75% from safe infusion products, 26.27% from blood purification, and 24.98% from other categories [1] Shareholder Information - Among the top circulating shareholders, one fund from Huaxia Fund holds a significant position, having reduced its holdings by 1.0661 million shares in Q3, now holding 2.6036 million shares, which is 1.57% of circulating shares [2] - The Huaxia Industry Prosperity Mixed A Fund (003567) was established on February 4, 2017, with a current scale of 7.261 billion CNY and a year-to-date return of 56.47%, ranking 837 out of 8155 in its category [2] - The fund manager, Zhong Shuai, has a tenure of 5 years and 94 days, with the best fund return during this period being 177.53% and the worst being -2.4% [2]

Group 1 - The core viewpoint of the news is that Maide Medical has seen a stock price increase of 5.16%, reaching 20.77 CNY per share, with a total market capitalization of 3.452 billion CNY [1] - Maide Medical, established on March 10, 2003, and listed on December 3, 2019, specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1] - The company's main business revenue composition includes: 48.75% from safe infusion products, 26.27% from blood purification, and 24.98% from other categories [1] Group 2 - From the perspective of fund holdings, one fund under Guotai Fund has a significant position in Maide Medical, with 200,000 shares held, accounting for 1.08% of the fund's net value [2] - The Guotai Ju Li Value Flexible Allocation Mixed Fund (005746) has a current scale of 273 million CNY and has achieved a year-to-date return of 5.34% [2] - The fund's performance ranks 6799 out of 8243 in its category for the year and has a cumulative return of 46.8% since its inception [2]

Core Insights - The medical consumables intelligent equipment industry is experiencing a dual upgrade in scale and quality, driven by the transformation of the manufacturing sector and the localization of medical devices [1][2] - Midea Medical Industrial Equipment Co., Ltd. (stock code: 688310) has over 20 years of experience in the medical consumables intelligent equipment sector, focusing on technological innovation and establishing core competitiveness in areas such as safe infusion and blood purification [1][2] Industry Overview - The Chinese medical device industry is projected to reach a total scale of 1.2 trillion yuan by 2025, with high-value consumables accounting for over 30%, corresponding to a market size exceeding 360 billion yuan [2] - The blood purification product segment is expected to grow significantly, with a market size of approximately 18.7 billion yuan in 2024, reflecting a year-on-year growth of 10% due to the rising number of end-stage renal disease (ESRD) patients [2] - The number of ESRD patients in China reached 4.1259 million in 2023 and is expected to increase to 5.2713 million by 2027, driving demand for automated production equipment for dialysis consumables [2] - The pre-filled syringe market is expanding rapidly, supported by the biopharmaceutical, medical aesthetics, and vaccine sectors, with a shift from Western markets to domestic production [2] - The "14th Five-Year" medical equipment industry development plan emphasizes support for the localization of high-end medical equipment, aiming for over 50% of county-level hospitals to procure domestic CTs by 2025 [2] Company Performance - Midea Medical focuses on intelligent equipment for medical consumables, including safe infusion, blood purification, and drug-device combination solutions, offering a full chain of solutions from single machines to connected systems [3] - The company has made significant advancements in blood purification equipment, breaking foreign monopolies with its domestically produced medical dialysis equipment [3] - Despite market fluctuations and longer production cycles, the company demonstrated resilience with R&D investment reaching 17.9772 million yuan, accounting for 12.75% of revenue, an increase of 0.48 percentage points year-on-year [4] - The net cash flow from operating activities reached 110 million yuan, a substantial year-on-year increase of 243.90%, indicating improved cash flow [4] Competitive Advantages - The company possesses strong core competencies across technology, R&D, customer relations, and market presence, with 18 key technologies, including advanced solvent bonding technology that reduces glue usage by 20% [5] - Midea Medical has established long-term partnerships with leading domestic medical consumables companies and has entered the supply chains of international clients [5] - The company has maintained the highest market share in its industry for three consecutive years from 2022 to 2024, showcasing its significant first-mover advantage [5] New Business Development - Midea Medical is expanding its growth avenues through its subsidiary, Midea Shun, which is focusing on the contact lens CDMO business, addressing domestic outsourcing gaps [6] - The company is also making strides in international markets by building overseas R&D and sales networks, aiming to extend its cost and technological advantages globally [6]

Core Viewpoint - Midea Medical's stock rose by 5.79% on September 16, reaching 20.66 yuan per share, with a total market capitalization of 3.434 billion yuan [1] Company Overview - Midea Medical Industrial Equipment Co., Ltd. is located in Yuhuan City, Zhejiang Province, established on March 10, 2003, and listed on December 3, 2019. The company specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1] - The main business revenue composition includes: 42.18% from safe infusion line machines, 37.90% from blood purification line machines, 14.04% from safe infusion single machines, and 5.87% from other categories [1] Fund Holdings - According to data from the top ten heavy stocks of funds, one fund under Guotai Fund holds a significant position in Midea Medical. The Guotai Value Flexible Allocation Mixed Fund (005746) held 200,000 shares in the second quarter, accounting for 1.08% of the fund's net value, ranking as the eighth largest heavy stock [2] - The fund has generated an estimated floating profit of approximately 226,000 yuan today [2] Fund Performance - The Guotai Value Flexible Allocation Mixed Fund (005746) was established on March 27, 2018, with a latest scale of 273 million yuan. Year-to-date returns are 5.47%, ranking 6623 out of 8174 in its category; the one-year return is 10.46%, ranking 6881 out of 7982; and since inception, the return is 46.99% [2] Fund Managers - The fund managers are Cheng Zhou and Cheng Yao. Cheng Zhou has a cumulative tenure of 17 years and 171 days, with a total fund asset scale of 6.594 billion yuan, achieving a best fund return of 361.33% and a worst return of -37% during his tenure [3] - Cheng Yao has a cumulative tenure of 4 years and 71 days, managing a total fund asset scale of 1.921 billion yuan, with a best fund return of 14.74% and a worst return of 3.78% during her tenure [3]

Group 1 - The core viewpoint of the news is that Maide Medical's stock has experienced a decline of 5.07%, with a current price of 19.47 CNY per share and a total market capitalization of 3.236 billion CNY [1] - Maide Medical, established on March 10, 2003, and listed on December 3, 2019, specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1] - The main revenue composition of Maide Medical includes: 42.18% from safety infusion line machines, 37.90% from blood purification line machines, 14.04% from safety infusion single machines, and 5.87% from other categories [1] Group 2 - Among the top ten circulating shareholders of Maide Medical, a fund under Rongtong Fund holds a position, having reduced its holdings by 156 shares in the first quarter, now owning 2.5998 million shares, which is 1.56% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) has a current scale of 2.074 billion CNY and has achieved a return of 23.63% this year, ranking 3072 out of 8194 in its category [2] - The fund has a one-year return of 47%, ranking 2642 out of 7963, and a cumulative return since inception of 198.7% [2]

Main Business - The company's main products include safety infusion devices and blood purification equipment, with significant revenue declines in safety infusion single machines and blood purification single machines, down 39.59% and 100.00% respectively, while blood purification continuous machines saw substantial growth [2][5][6] - The first major customer accounted for a significant portion of annual sales, with the increase in transaction amount attributed to the growth in the blood purification product business and the overall industry [2][14] Supplier Information - The company sources all standard parts externally, with a mix of self-manufactured, custom procurement, and outsourced processing for non-standard components. The total procurement amount for 2024 was 23,959.42 million yuan, a decrease of 36.99% compared to the previous year [28][29] Inventory and Contract Liabilities - The company reported that the inventory of blood purification single machines remained unsold due to production cycle delays and customer facility issues, impacting revenue recognition [11][12] - The company maintains a production model based on order fulfillment, which has led to fluctuations in sales revenue for blood purification single machines [11][12] Accounts Receivable and Long-term Receivables - The company provided details on its top five customers, including transaction amounts and payment conditions, indicating a healthy receivables situation with good recovery rates [13][15] Goodwill Impairment - There were no indications of impairment for the company's assets, as the net realizable value of blood purification single machines exceeded their costs, negating the need for inventory write-downs [12][25] Construction in Progress - The company has invested in the development of its contact lens manufacturing subsidiary, with a focus on material research and production line construction, indicating a strategic expansion into the optical sector [3][24] Market Trends - The blood dialysis medical device market in China is projected to grow steadily, with a compound annual growth rate of 5.67% from 2019 to 2023, expected to reach 51.515 billion yuan by 2030 [6][14] - The company is also expanding into the contact lens market, which is anticipated to grow significantly, with the transparent and colored contact lens markets projected to reach 161 billion yuan and 183 billion yuan respectively by 2030 [18][20]

Company Overview - Maide Medical's stock closed at 14.61 yuan, up 1.67%, with a latest price-to-book ratio of 3.09, marking a new low in 231 days, and a total market capitalization of 2.428 billion yuan [1] - As of the first quarter of 2025, five institutions held shares in Maide Medical, including three funds, one other entity, and one social security fund, with a total holding of 15.2835 million shares valued at 179 million yuan [1] - The company specializes in the research, production, sales, and service of medical consumables and intelligent equipment, with main products including safety infusion and blood purification devices [1] Performance Metrics - For the first quarter of 2025, Maide Medical reported operating revenue of 40.1763 million yuan, a year-on-year decrease of 45.87%, and a net profit of -10,797,370.24 yuan, a year-on-year decline of 202.70%, with a gross profit margin of 32.89% [1] - The company's price-to-earnings ratio (TTM) is -58.81, and the static PE is -121.54, with a market capitalization of 2.428 billion yuan [2] - The industry average PE (TTM) is 60.04, and the industry median is 49.67, indicating that Maide Medical's valuation metrics are significantly lower than the industry averages [2]

Core Viewpoint - MaiDe Medical's stock closed at 14.03 yuan, up 3.47%, with a latest price-to-book ratio of 2.97, marking a new low in 156 days, and a total market capitalization of 2.332 billion yuan [1] Group 1: Company Overview - MaiDe Medical Industrial Equipment Co., Ltd. specializes in the research, development, production, sales, and service of medical consumables and intelligent equipment [1] - The company's main products include safety infusion and blood purification equipment [1] - The company has been recognized with qualifications such as the establishment of a postdoctoral workstation in Zhejiang Province and participation in various provincial projects [1] Group 2: Financial Performance - As of the first quarter of 2025, the company reported operating revenue of 40.1763 million yuan, a year-on-year decrease of 45.87% [1] - The net profit for the same period was -10,797,370.24 yuan, reflecting a year-on-year decline of 202.70% [1] - The sales gross margin stood at 32.89% [1] Group 3: Institutional Holdings - As of the first quarter of 2025, five institutions held shares in MaiDe Medical, including three funds, one other institution, and one social security fund, with a total holding of 15.2835 million shares valued at 17.9 million yuan [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Maide Medical, indicating a significant decline in revenue and profit for the third quarter of 2024 [1] - As of September 30, 2024, Maide Medical has 4,462 shareholders, an increase of 520 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, sales, and service of medical consumables and intelligent equipment, with key products in safety infusion and blood purification [1] Group 2 - The latest financial results show that Maide Medical achieved an operating income of 220 million yuan, a year-on-year decrease of 33.45%, and a net profit of 7.63 million yuan, down 89.37% year-on-year, with a gross profit margin of 48.86% [1] - The company's current price-to-earnings ratio (TTM) is -90.14, and the price-to-book ratio is 2.12, with a total market capitalization of 1.78 billion yuan [2] - Compared to industry averages, Maide Medical's financial metrics are significantly lower, with the industry average P/E ratio at 59.86 and average price-to-book ratio at 4.03 [2]